![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.005 | 0.11% | 4.65 | 4.41 | 4.89 | 4.53 | 4.51 | 4.53 | 241,784 | 16:35:17 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.51 | 9.35M |
Date | Subject | Author | Discuss |
---|---|---|---|
11/7/2020 10:35 | This is worth a read. Published a few days ago Are we fully exploiting type I Interferons in today's fight against COVID-19 pandemic? Highlights IFN-I, in particular IFN-β, are promising drugs for SARS-CoV2 infection Early infection in elderly patients is the best setting to exploit IFN-I immunomodulatory activity Caution should be given in using continuous IFN-I treatments at high doses. Mucosal IFN-I delivery is promising but deserves further clinical investigation Attention should be paid to IFN-I treatment in patients with severe COVID-19 | ![]() waterloo01 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions